BioCatalystWatch
ABSIWorkspace / ABSI / OverviewCompany library
Price
Market cap
Next catalystDec 2026ABS-201 — HEADLINE · Phase 1/2 dataCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

ABS-201

Antibody

PRLR

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

ABS-201

Antibody

PRLR

PreINDP1P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

ABS-201

Antibody

PRLR

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

ABS-201

Antibody

PRLR

PreINDP1P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Other pipelines

ABS-301

Antibody

PreINDP1P2P3FilingApproved
ABS-501

Antibody

HER2

PreINDP1P2P3FilingApproved

Partner / License out

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

ABSI PR & News

ABSI SEC archive